Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Akebia Therapeutics (AKBA) over the last 5 years, with Sep 2025 value amounting to $274.4 million.

  • Akebia Therapeutics' Shares Outstanding (Diluted Average) rose 30.44% to $274.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.4 million, marking a year-over-year increase of 30.44%. This contributed to the annual value of $210.9 million for FY2024, which is 12.53% up from last year.
  • Per Akebia Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $274.4 million for Q3 2025, which was up 1.21% from $271.1 million recorded in Q2 2025.
  • Akebia Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $274.4 million during Q3 2025, with a 5-year trough of $153.8 million in Q1 2021.
  • Over the past 3 years, Akebia Therapeutics' median Shares Outstanding (Diluted Average) value was $209.7 million (recorded in 2024), while the average stood at $215.5 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Shares Outstanding (Diluted Average) fell by 1.87% in 2023, and later soared by 30.44% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $165.9 million in 2021, then climbed by 10.14% to $182.8 million in 2022, then rose by 2.56% to $187.5 million in 2023, then climbed by 12.53% to $210.9 million in 2024, then surged by 30.44% to $274.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $274.4 million in Q3 2025, compared to $271.1 million in Q2 2025 and $241.6 million in Q1 2025.